BiotechTube

Subcutaneous Decitabine

Phase 1Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndrome

Conditions

Myelodysplastic Syndrome

Trial Timeline

Oct 1, 2006 → Feb 1, 2009

NCT ID
NCT00282399

About Subcutaneous Decitabine

Subcutaneous Decitabine is a phase 1 stage product being developed by Eisai for Myelodysplastic Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT00282399. Target conditions include Myelodysplastic Syndrome.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00282399Phase 1Terminated

Competing Products

20 competing products in Myelodysplastic Syndrome

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
28
JSP191Jasper TherapeuticsPhase 1
25
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
25
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
33
Erlotinib HydrochlorideAstellas PharmaPhase 2
52
Decitabine + Decitabine + DecitabineEisaiPhase 2
52
Decitabine + Valproic AcidEisaiPhase 2
52
decitabine + decitabineEisaiPhase 2
52
decitabine + azacitidineEisaiApproved
85
DecitabineEisaiPhase 2
52
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
33
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
52
DecitabineEisaiPhase 2
52
Galunisertib + PlaceboEli LillyPhase 2/3
65
DSP-7888Sumitomo PharmaPhase 1/2
41
TP-0184Sumitomo PharmaPhase 1/2
41
DecitabineJohnson & JohnsonPhase 2
52
Epoetin alfaJohnson & JohnsonPhase 2
52
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
52
DecitabineJohnson & JohnsonPhase 2
52

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85